equityflowunderstand the flow and follow it

EquityFlow › Companies › bit.bio

bit.bio

Biotech · Cambridge, GB

Human cell coding company using OPTi-OX reprogramming technology.

Founders

Mark Kotter (Canada · ♂) — A Cambridge neurosurgeon and stem cell biologist, Kotter spun his opti-ox cell-coding technology out of the university in 2016 (as Elpis Biomed, later bit.bio) to reliably reprogram stem cells into defined human cell types at scale.

Team & hubs

Funding history

Date	Round	Amount
Nov 2021	Series B Cambridge cell-coding biotech bit.bio raised a USD 103M Series B with Arch Ventures, Tencent and others.	$103M

Investors

Tap an investor to see what else they have backed.

Arch Ventures Charles River Laboratories Foresite Capital Tencent

Other companies in Biotech

Imperagen Haga Bioscience Pixelgen Technologies Gallant Chai Discovery SNIPR Biome Cellbox Labs Scope Biosciences GenLumina Actithera NUCLIDIUM Anocca

Other companies in GB

Capsa AI 01Health Rem3dy Health NewOrbit Joyvié Health Fuse Energy Airspeed Semble Wordsmith Oxford Quantum Circuits Fresha Imperagen

Other companies at Series B stage

0x Labs 11x.ai 1K Kirana 1X Technologies 1plusX 3Commas 3SC 4baseCare 4screen 8fig 9fin ACALL

Explore funding flow on EquityFlow →

Data is community-curated and may be incomplete.